Drug resistance reversal - are we getting closer?

被引：127

作者：

Baird, RD

Kaye, SB ^{[1
]}

机构：

[1] Inst Canc Res, Med Sect, Sutton SM2 5PT, Surrey, England

[2] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England

[3] Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England

来源：

EUROPEAN JOURNAL OF CANCER | 2003年 / 39卷 / 17期

关键词：

drug resistance; ovarian cancer; carboplatin; paclitaxel; platinum compounds; chemotherapy; DNA repair; thymidylate synthase; signal transduction; DNA methylation;

D O I：

10.1016/S0959-8049(03)00619-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical drug resistance is a major barrier to overcome before chemotherapy can become curative for most patients presenting with metastatic cancer. Rational attempts to tackle clinical drug resistance need to be based on an understanding of the mechanisms involved; these are likely to be complex and multifactorial, and may be due to inadequate drug exposure or alterations in the cancer cell itself. This article reviews a number of strategies used to tackle drug resistance, focussing on work in our institution related to the treatment of ovarian cancer and resistance to platinum and taxane-based chemotherapy. Further progress towards drug resistance reversal will require a three-pronged approach, namely: the development of novel cytotoxics which exploit selectively expressed targets; modulation of resistance to conventional agents and, most importantly, a serious attempt to understand resistance mechanisms in tumour samples taken both pre- and post-chemotherapy. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：2450 / 2461

页数：12

共 106 条

[11] Expression of multidrug resistance-associated markers, their relation to quantitative pathologic tumour characteristics and prognosis in advanced ovarian cancer [J].